| Original language | American English |
|---|---|
| State | Published - 2013 |
| Event | ASCO 2013 - Chicago, IL Duration: Jan 1 2013 → … |
Conference
| Conference | ASCO 2013 |
|---|---|
| Period | 1/1/13 → … |
Disciplines
- Medicine and Health Sciences
Serum and tumor biomarkers predict outcome in the elung trial, a multicenter, randomized phase 2b study of standard platinum doublets (PD) plus cetuximab (CET) as first-line treatment of advanced non-small cell lung cancer (NSCLC)
Bruno Bastos
Research output: Contribution to conference › Presentation